Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics.